Conclusion
The insect cell as host for protein production is relative new. Therefore few data are available. This creates a vicious circle because it makes the choice of insect cells as basis for a pharmaceutical process less attractive. There are three main issues when comparing insect-cells to “traditional” systems as mammalian and bacterial cells. First, since the expression vector is not incorporated in the cells, a virus stock similar to the cell bank system has to be laid down and tested. This will cost time and money. Secondly the vector is subject to mutation and therefore the decrease in infectivity has to be characterized and validated. Third, the post-translational modification of the protein may differ. None of the mentioned issues, however, forms an obstacle that can not be overcome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Davidson JJ & Castellino FJ (1991) Asparagine-linked oligosaccharide processing in Lepidopteran insect cells. Temporal dependence of the nature of the oligosaccharides assembled on Asparagine?289 of recombinant human plasminogen produced in baculovirus vector infected Spodoptera frugiperda (IPLB-SF-21AE) cells. Biochem. 30: 6167–6174.
Kompier R, Tramper J & Vlak JM (1988) A continuous process for production of baculovirus using insect-cell cultures. Biotechnol. Letters 10: 849–854.
McLean C & Sheperd AJ (1994) The application of insect cells for biopharmaceutical production: implications for safety testing. In Spier RE, Griffiths JB & Berthold W (eds) Animal cell technology: Products of today, prospects of tomorrow, (pp. 769–774) Butterworth-Heinemann Ltd, Oxford.
Points to consider in the characterization of cell lines used to produce biologicals (1993). Center for Biologics Evaluation and Research, Food and Drugs Administration, Rockville.
Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis D, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Schafferman A, Volvovitz F, Oster C & Burke DS (1991) A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Eng. J. Med. 324: 1677–1684.
Van Lier FLJ, van der Meijs WCJ, Grobben NA, Olie RA, Vlak JM & Tramper J (1991) Continuous β-galactosidase production with a recombinant baculovirus insect-cell system in bioreactors. J. Biotechnol. 22: 291–298.
Van Lier FLJ, van den Hombergh JPTW, de Gooijer CD, den Boer MM, Vlak JM & Tramper J (1996) Long-term semi-continuous production of recombinant baculovirus protein in a repeated (fed) batch two-stage bioreactor system. Enzyme Microb. Technol. 18: 460–466.
Zhang J, Kalogerakis N, Behie LA & latrou K (1993) A two-stage bioreactor system for the production of recombinant proteins using a genetically engineered baculovirus/insect cell system. Biotechnol. Bioeng. 42: 357–366.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
van Lier, F.L. (1996). Regulatory issues in the use of insect-cell culture. In: Vlak, J., de Gooijer, C., Tramper, J., Miltenburger, H. (eds) Insect Cell Culture: Fundamental and Applied Aspects. Current Applications of Cell Culture Engineering, vol 2. Springer, Dordrecht. https://doi.org/10.1007/0-306-46850-6_27
Download citation
DOI: https://doi.org/10.1007/0-306-46850-6_27
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-3403-3
Online ISBN: 978-0-306-46850-6
eBook Packages: Springer Book Archive